AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03802396
Drug: CN-105
RxNorm normalized name: CN-105
DrugBank: CN-105 (DB18345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of CN-105 will be used in three successive cohorts of 50 patients each.~0.1 mg/kg (cohort 1), 0.5 mg/kg (cohort 2), 1 mg/kg (cohort 3)~The study drug will be administered by IV every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses.
Trial: NCT00424060
Drug: sagopilone
RxNorm normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00543127
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.
Trial: NCT00543127
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg oral Anastrozole per day during 5 years.
Trial: NCT04701710
Drug: Ivermectin / Iota-Carrageenan
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.
Trial: NCT03834740
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib administered orally in 5 daily doses prior to resection
Trial: NCT03834740
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus administered orally in 5 daily doses prior to resection
Trial: NCT01107886
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg or 2.5 mg once daily
Trial: NCT01354093
Drug: zeaxanthin
RxNorm normalized name: Zeaxanthin
DrugBank: Zeaxanthin (DB11176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
Trial: NCT01354093
Drug: zeaxanthin
RxNorm normalized name: Zeaxanthin
DrugBank: Zeaxanthin (DB11176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
Trial: NCT00314613
Drug: Antipsychotic/Risperidone Consta
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02882347
Drug: Somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02724202
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
Trial: NCT01657981
Drug: YM150
RxNorm normalized name: Yohimbine
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14C-labeled YM150, oral solution
Trial: NCT00861887
Drug: Standard Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin treatment 125 mg po every 6 hours x 2 weeks
Trial: NCT00861887
Drug: Extended Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin 125 mg every 6 hours x 2 weeks
Trial: NCT03262961
Drug: Sildenafil 20 MG
RxNorm normalized name: sildenafil 20 MG
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01246960
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT01246960
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT02550145
Drug: Exendin (9-39)
RxNorm normalized name: EXENDIN (9-39)
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
Trial: NCT00980044
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Medication
Trial: NCT01409096
Drug: Pregnenolone
RxNorm normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.
Trial: NCT02172729
Drug: Adductor canal block with 20 ml lidocaine, single bolus
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
Trial: NCT04518501
Drug: Arsenic trioxide Tablet +Fuzuloparib Capsules
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po
Trial: NCT03440385
Drug: Ozanimod
RxNorm normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT02301897
Drug: Telapristone Acetate
RxNorm normalized name: Telapristone acetate
DrugBank: Telapristone acetate (DB05253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
Trial: NCT02965781
Drug: SADBE
RxNorm normalized name: LEMON 5 g in 50 g / VIOLA ODORATA FLOWER 10 g in 50 g / TOCOPHEROL 5 g in 50 g TOPICAL CREAM [XIMONTH Violette Beruhigende Hauttherapie Salbe]
DrugBank: Lemon (DB10538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution
Trial: NCT02675400
Drug: Vyvanse
RxNorm normalized name: Vyvanse
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Half of the participants (fathers) will be randomized to receive Vyvanse.
Trial: NCT02675400
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If Vyvanse is not well tolerated, methylphenidate can be prescribed.
Trial: NCT02179034
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
Trial: NCT02538614
Drug: Idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets administered orally twice daily
Trial: NCT02538614
Drug: BI 836826
RxNorm normalized name: BI 836826
DrugBank: BI-836826 (DB17322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration as a rate-controlled infusion
Trial: NCT01605994
Drug: BMS-933043
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01347814
Drug: Domperidone 10mg
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg domperidone tablet 30 minutes before a test-meal.
Trial: NCT00314977
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
Trial: NCT03474276
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Albendazole at inclusion of the child : 200mgs, one administration
Trial: NCT00000600
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000600
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02288130
Drug: GnRHa
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02288130
Drug: Ulipristal
RxNorm normalized name: Ulipristal
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03116126
Drug: Guanfacine
RxNorm normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2mg oral daily tablet
Trial: NCT03251508
Drug: Peanut OIT
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given increasing doses of the peanut flour as peanut oral immunotherapy (OIT) with increasing doses every 2 weeks over a period of 3 months up to a 300 mg target dose. This 300 mg peanut OIT maintenance dose is then continued daily for 3 months. Participants will then introduce dietary peanut of approximately 300 mg of peanut protein and continue daily ingestion for an additional 6 months.
Trial: NCT00064857
Drug: Pycnogenol
RxNorm normalized name: Pycnogenol
DrugBank: Maritime pine extract (DB15786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02940548
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 30\~60mg/day for 8 weeks
Trial: NCT02940548
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate 5\~10mg/day for 8 weeks
Trial: NCT02328495
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Trial: NCT00004128
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004128
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004128
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004128
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04507204
Drug: Adhansia XR
RxNorm normalized name: Adhansia XR
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)
Trial: NCT04507204
Drug: Concerta
RxNorm normalized name: Concerta
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)
Trial: NCT04997850
Drug: lenvatinib + sindilimab/carrelizumab
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next treatment cycle was carried out. The trial was terminated if the drug was stopped for more than 28 days due to adverse drug reactions or other reasons. Patients with PD after 6 cycles of sindilimab/carrelizumab treatment were terminated. The follow-up treatment was based on the principle of individualization, multidisciplinary discussion and patients' willingness.
Trial: NCT01702298
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will continue pre-study dose of metformin tablet(s) \>=1000 per day
Trial: NCT04217265
Drug: Letrozole then misoprostol
RxNorm normalized name: Letrozole
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: total dose 5 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
Trial: NCT04217265
Drug: placebo then misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo tablets for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
Trial: NCT02522767
Drug: Mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02633371
Drug: Oxybutynin 3% gel
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01255774
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An open-label, study of intravitreally administered ranibizumab
Trial: NCT05530057
Drug: Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.~* Dose reductions for eribulin, but not for SB3, is permitted.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed for eribulin before consideration of study treatment discontinuation. Eribulin could be continued as monotherapy if trastuzumab-similar was discontinued, and vice-versa.
Trial: NCT05530057
Drug: Eribulin Mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed before consideration of study treatment discontinuation.
Trial: NCT00624052
Drug: fixed-dose combination of telmisartan 40mg+amlodipine 10mg
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00624052
Drug: fixed-dose combination of telmisartan 80mg+amlodipine10mg
RxNorm normalized name: telmisartan 80 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02576288
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: anti-inflammatory properties
Trial: NCT02494596
Drug: RhuMab 2C4
RxNorm normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
Trial: NCT01186757
Drug: PF-03715455
RxNorm normalized name: PF-03715455
DrugBank: PF-03715455 (DB12138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-03715455 1.6 mg BID
Trial: NCT01186757
Drug: PF-03715455
RxNorm normalized name: PF-03715455
DrugBank: PF-03715455 (DB12138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-03715455 4mg BID
Trial: NCT01186757
Drug: PF-03715455
RxNorm normalized name: PF-03715455
DrugBank: PF-03715455 (DB12138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-03715455 10 mg BID
Trial: NCT01785030
Drug: 50% Nitrous oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04587492
Drug: Nusinersen
RxNorm normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with nusinersen
Trial: NCT04183686
Drug: ACT-1014-6470 (SAD)
RxNorm normalized name: ACT-541468
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ACT-1014-6470; soft capsules for oral use.
Trial: NCT02538302
Drug: Minirin
RxNorm normalized name: Minirin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Minirin 5 to 10 mg daily for 6 months
Trial: NCT02538302
Drug: Oxybutynin
RxNorm normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxybutynin 5 to 10 mg daily for 6 months
Trial: NCT04183686
Drug: ACT-1014-6470 (MAD)
RxNorm normalized name: ACT-541468
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of ACT-1014-6470; soft capsules for oral use.
Trial: NCT04183686
Drug: 14C-ACT-1014-6470 microtracer
RxNorm normalized name: ACT-541468
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 14C-ACT-1014-6470 microtracer; soft capsules for oral use.
Trial: NCT04183686
Drug: 14C-ACT-1014-6470 microtracer placebo
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching placebo; soft capsules for oral use.
Trial: NCT03322566
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab administered intravenously every 3 weeks.
Trial: NCT03322566
Drug: Epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat administered orally twice daily.
Trial: NCT03322566
Drug: Platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.
Trial: NCT03202394
Drug: BIO-11006
RxNorm normalized name: BIO-11006
DrugBank: BIO-11006 (DB14886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer.
Trial: NCT01438918
Drug: SD-6010
RxNorm normalized name: Alphanine SD
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tablets once a day for 2 years
Trial: NCT00560417
Drug: Insulin Lispro Protamine Suspension
RxNorm normalized name: Insulin Lispro Protamine Suspension and Insulin Lispro Injection
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered subcutaneously once a day at bedtime
Trial: NCT00560417
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered subcutaneously once a day at bedtime
Trial: NCT00070304
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV over 100 minutes dose 1000 mg/m2/dose in 500 ml NS on days 1 and 8
Trial: NCT00070304
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV over 6-10 minutes (central venous catheter). Dose 25 mg/m2/dose on days 1 and 8
Trial: NCT02736071
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Women will receive oral Tramadol 100mg 2 hours before the procedure
Trial: NCT03781063
Drug: Lasofoxifene
RxNorm normalized name: lasofoxifene
DrugBank: Lasofoxifene (DB06202)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Estrogen receptor antagonist antineoplastic agent
Trial: NCT03781063
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estrogen receptor antagonist antineoplastic agent
Trial: NCT00095550
Drug: Irbesartan/HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
Trial: NCT00095550
Drug: Irbesartan monotherapy
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 150 mg, Once daily, 12 weeks.
Trial: NCT00095550
Drug: HCTZ monotherapy
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
Trial: NCT04600284
Drug: AD-2101
RxNorm normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AD-2101 16/5mg
Trial: NCT04600284
Drug: AD-2102
RxNorm normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AD-2102 25mg
Trial: NCT04600284
Drug: AD-2101 + AD-2102
RxNorm normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AD-2101 16/5mg + AD-2102 25mg
Trial: NCT00553254
Drug: PF-00299804
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
Trial: NCT00398814
Drug: Perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.